John R. van Nagell Jr., MD

Director, Ovarian Cancer Screening Program

Clinical interests

  • Gynecologic Cancer
  • Ovarian Cancer Screening
  • Ovarian Cancer

John R. van Nagell Jr., MD

Director, Ovarian Cancer Screening Program

Biography

My name is John R. van Nagell; I received my medical degree from the University of Pennsylvania, School of Medicine, Philadelphia. I then completed a fellowship at the University of Kentucky, Lexington.

I am board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology. I am an American Cancer Society Professor of Clinical Oncology, and am the past president of the Society of Gynecologic Oncology.

Faculty rank

Professor of Obstetrics and Gynecology

Education

Degree
University of Pennsylvania, School of Medicine, Philadelphia

Residency
University of Kentucky, Lexington

Fellowship
University of Kentucky, Lexington

Certifications or Special training
American Board of Obstetrics and Gynecology
American Board of Obstetrics and Gynecology, Gynecologic Oncology

Gynecologic Oncology

Gynecologic Oncology Clinic

Markey Cancer Center
Whitney-Hendrickson Building
Third Floor, Room 330A
800 Rose St.
Lexington KY 40536-0098

Call 859-323-5553
Call 866-340-4488
Fax 859-323-1602

Directions to Markey Cancer Center »


UK HealthCare accepts many forms of insurance. See list of insurers »

 

Recent Publications

(Five most recent publications from PubMed via an automated list based on the provider’s ID and the University of Kentucky.)
  1. Lefringhouse JR, Neward E, Ueland FR, Baldwin LA, Miller RW, DeSimone CP, Kryscio RJ, van Nagell JR, Pavlik EJ.
    Probability of fallopian tube and ovarian detection with transvaginal ultrasonography in normal women.
    Womens Health (Lond Engl). 2016 Jun;12(3):303-11.
  2. van Nagell JR, Miller RW.
    Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women.
    Obstet Gynecol. 2016 May;127(5):848-58.
  3. Ormsby EL, Pavlik EJ, van Nagell JR.
    Ultrasound follow up of an adnexal mass has the potential to save lives.
    Am J Obstet Gynecol. 2015 Nov;213(5):657-61, 657.e1.
  4. Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z, Erfani S, Jin H, Xu M, She QB, van Nagell JR, Wang C, Chen L, Plattner R, Kaetzel DM, Luo J, Lu M, West D, Liu C, Ueland FR, Drapkin R, Zhou BP, Yang XH.
    CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling.
    Oncotarget. 2014 Dec 15;5(23):12203-17.
  5. Elder JW, Pavlik EJ, Long A, Miller RW, DeSimone CP, Hoff JT, Ueland WR, Kryscio RJ, van Nagell JR, Ueland FR.
    Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index.
    Gynecol Oncol. 2014 Oct;135(1):8-12.

View this provider on PubMed